LOGIN  |  REGISTER
Assertio

BioCorRx (OTCMKTS: BICX) Stock Quote

Last Trade: US$0.84 0.04 5.56
Volume: 135
5-Day Change: 2.58%
YTD Change: 7.18%
Market Cap: US$7.190M

Latest News From BioCorRx

ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors. Dr. DeVarney spearheaded the development of Probuphine® (buprenorphine implant), the... Read More
ANAHEIM, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, announced the appointment of Louis Lucido as Interim President of the Company, effective immediately through January 31, 2024, and he will assume the formal role as President on February 1, 2024. Mr. Lucido will... Read More
ANAHEIM, CA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended September 30, 2023, and reported on recent corporate developments. Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “We believe that the... Read More
Company Hopes in 30 Days to Begin Making Its Drug Candidate Available to Help Patients and Address Public Health Crisis ANAHEIM, CA, Aug. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) today announced its submission to the US Food and Drug Administration (FDA) of an expanded access program application for BICX104 (implantable naltrexone pellet) for the treatment of opioid use... Read More
On Track to Meet 2023 Regulatory Milestones ANAHEIM, CA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended June 30, 2023, and reported on recent corporate developments. Lourdes Felix, CEO, CFO, and Director of BioCorRx... Read More
ANAHEIM, CA, July 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced the submission of a fast track application to the U.S. Food and Drug Administration (“FDA”) for BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD).... Read More
Revenue Increases 97% ANAHEIM, CA, May 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended March 31, 2023 and reported on recent corporate developments. Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented,... Read More
Revenue Increases 343% for 2022 Due to Increased Number of Patients Treated at Licensed Clinics ANAHEIM, CA, April 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2022 and reported on recent corporate developments.... Read More
BICX104 was Well Tolerated with No Serious Adverse Events Reported and Achieved 84 Days of Therapeutic Naltrexone Plasma Concentrations BICX104 Subjects Experienced Better 84-Day Treatment Adherence Than Vivitrol® Subjects Company Seeking FDA Approval for Immediate Expanded Access “Compassionate Use” of BICX104 for Over 10 Million Americans with Opioid Use Disorder BioCorRx Applying for Fast Track Designation and Also... Read More
ANAHEIM, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance use and related disorders, announced today that Dr. Andrew Mallon, CSO and Grant Principal Investigator on the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD),... Read More
Presentation on Thursday, February 2, 2023 at 2:00 PM ET ANAHEIM, CA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance use and related disorders, announced today that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx, and Brady Granier, President and Director of... Read More
ANAHEIM, CA, Jan. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance use and related disorders, today announced that Mr. Harsha Murthy was appointed to the Company’s Board of Directors. Mr. Harsha Murthy is an experienced pharmaceuticals/finance executive with expertise in pharmaceutical operations, strategy,... Read More
ANAHEIM, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance use and related disorders, today announced an update from the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx... Read More
FREEHOLD, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, today announced that it has appointed Lourdes Felix to its Board of Directors. Lourdes Felix is an entrepreneur and corporate finance executive with 30 years of combined experience in capital... Read More
ANAHEIM, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has partnered with Government Plus LLC, a leading provider of private sector healthcare to veterans, to nationally expand its Beat Addiction Recovery Program. Ed LeTourneau, CEO of... Read More
ANAHEIM, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the third quarter ended September 30, 2022 and reported on recent corporate developments. Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented, “Last month, we... Read More
BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., and Brady Granier, President, Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be presenting at the 15 th annual LD Micro Main Event being... Read More
BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., and Brady Granier, President, Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be participating at the 15 th annual LD Micro Main Event... Read More
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the last subject has been enrolled in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled... Read More
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO, and Director of BioCorRx, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12th - 14th, 2022. The event will include virtual participation as well as in-person... Read More
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the second quarter ended June 30, 2022 and reported on recent corporate developments. Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented, “During the quarter, we dosed the first subject in the Phase I clinical trial of BICX104, an... Read More
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Brady Granier, President and Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be participating in the Benzinga All Access event taking place on July 15, 2022. Mr. Granier is scheduled to present on Friday, July 15, 2022, at 10:40 A.M.... Read More
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the first subject has been dosed in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled... Read More
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Tom Welch, Executive Vice President of BioCorRx Inc., was featured on LiveNOW from FOX. Mr. Welch discussed BioCorRx’s pilot program with 2B3D , a virtual, augmented, and mixed reality technology company, a first-of-its-kind post-traumatic stress disorder... Read More
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., and Brady Granier, President, Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be presenting at the LD Micro Invitational XII which is being... Read More
Collaboration to create a synergistic treatment offering, combining BioCorRx’s MAT treatment program and 2B3D virtual reality technology Plans toward expanding the offering to other at-risk groups upon evaluating results of pilot with veterans BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it is... Read More
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the first quarter ended March 31, 2022 and reported on recent corporate developments. Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented, “We are pleased to report progress on our upcoming first-in-human clinical trial of BICX104,... Read More
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has begun the recruiting and enrollment process for its first-in-human clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc.,... Read More
BioCorRx Inc. (OTCQB:BICX) (the "Company") , a developer and provider of innovative treatment programs fr substance abuse and related disorders, today announced that it will present at the Planet MicroCap Showcase 2022 on Wednesday, May 4, 2022 at 3:00 PM Pacific Time/ 6:00 PM Eastern Time at the Bally's Hotel & Casino in Las Vegas, NV. Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx... Read More
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has been awarded a supplemental grant of approximately $100,000 by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH) for the first-in-human clinical trial of BICX104, an implantable biodegradable naltrexone pellet... Read More
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a year-end business update for 2021 and reported on recent corporate developments. Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented, “In 2021, we achieved a number of important milestones and accomplishments. During the second quarter of 2021, we... Read More
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that management will be participating in two upcoming conferences. 2022 Virtual Growth Conference Management has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. -... Read More
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced it has received Independent Institutional Review Board (IRB) approval for the Company’s Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx... Read More
Assertio

COPYRIGHT ©2023 HEALTH STOCKS HUB